{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:22:59Z","timestamp":1719998579041},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.antiviral.2015.01.014","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T16:48:54Z","timestamp":1423327734000},"page":"45-47","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatment optimization of na\u00efve HCV-1 patients using IL28B, RVR and fibrosis stage"],"prefix":"10.1016","volume":"116","author":[{"given":"Lucio","family":"Boglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.01.014_b0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2013.07.040","article-title":"Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin","volume":"60","author":"Andriulli","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.01.014_b0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.antiviral.2014.03.016","article-title":"Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms","volume":"106","author":"Boglione","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.01.014_b0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jhep.2014.02.035","article-title":"Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools","volume":"61","author":"Boglione","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.01.014_b0020","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/hep.24636","article-title":"Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon\/ribavirin treatment in patients infected with hepatitis C virus genotype 1\/4","volume":"54","author":"D\u2019Avolio","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.014_b0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/FTD.0b013e318272e55a","article-title":"Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG\/IFN-RBV treatment","volume":"34","author":"D\u2019Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2015.01.014_b0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"EASL recommendations on treatment of hepatitis C 2014","volume":"61","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.01.014_b0035","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.014_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2014.04.008","article-title":"Resistance to hepatitis C virus protease inhibitors","volume":"8C","author":"Kieffer","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2015.01.014_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.gene.2012.10.030","article-title":"Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF\/RBV therapy using systematic meta-analysis","volume":"513","author":"Luo","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.antiviral.2015.01.014_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jcpt.12106","article-title":"Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis","volume":"39","author":"Park","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.01.014_b0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/liv.12066","article-title":"Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?","volume":"33","author":"Shiffman","year":"2013","journal-title":"Liver Int."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.01.014_b0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1478-3231.2011.02718.x","article-title":"Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?","volume":"32","author":"Shiffman","year":"2012","journal-title":"Liver Int."},{"issue":"344\u2013350","key":"10.1016\/j.antiviral.2015.01.014_b0065","first-page":"e342","article-title":"Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C","volume":"9","author":"Stattermayer","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T11:51:58Z","timestamp":1537876318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":13,"alternative-id":["S0166354215000273"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment optimization of na\u00efve HCV-1 patients using IL28B, RVR and fibrosis stage","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}